Protalix BioTherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 25, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	179	145	143	130	74	38
Market Cap Growth	46.23%	1.52%	9.81%	76.21%	94.49%	-69.98%
Enterprise Value	137.88	122.82	113.3	111.58	84.99	32.37
Last Close Price	2.23	1.80	1.88	1.78	1.37	0.83
PE Ratio	11.52	-	47.00	19.78	-	-
Forward PE	-	10.29	3.94	-	60.89	-
PS Ratio	2.36	2.74	2.67	1.98	1.55	0.99
PB Ratio	2.68	3.00	3.30	3.87	-6.93	-6.28
P/TBV Ratio	2.69	2.93	3.53	4.37	-	-
P/FCF Ratio	13.89	-	19.29	-	-	-
P/OCF Ratio	11.96	-	16.44	-	-	-
EV/Sales Ratio	1.81	2.33	2.12	1.70	1.78	0.84
EV/EBITDA Ratio	6.47	-	21.70	9.58	-	-
EV/EBIT Ratio	6.97	-	28.92	10.67	-	-
EV/FCF Ratio	10.61	-	15.33	-	-	-
Debt / Equity Ratio	0.10	0.14	0.09	0.14	-3.04	-5.35
Debt / EBITDA Ratio	0.40	-	1.06	2.26	-	-
Debt / FCF Ratio	0.65	-	0.75	-	-	-
Net Debt / Equity Ratio	-0.63	-0.45	-0.68	-0.55	-1.06	0.91
Net Debt / EBITDA Ratio	-2.00	5.44	-5.61	-1.57	-0.95	0.28
Net Debt / FCF Ratio	-3.28	1.61	-3.96	7.41	-0.44	0.47
Asset Turnover	0.83	0.68	0.68	0.93	0.74	0.54
Inventory Turnover	0.82	1.15	1.21	1.28	1.13	1.05
Quick Ratio	1.97	1.47	1.47	1.09	0.83	1.28
Current Ratio	3.15	2.51	2.34	1.54	1.38	1.86
Return on Equity (ROE)	30.01%	-10.09%	14.00%	76.93%	166.31%	166.80%
Return on Assets (ROA)	19.27%	-5.81%	6.42%	15.36%	-19.37%	-28.90%
Return on Invested Capital (ROIC)	68.14%	-21.65%	19.88%	35.10%	-53.39%	-41.22%
Return on Capital Employed (ROCE)	30.27%	-10.62%	9.04%	33.60%	-40.77%	-186.45%
Earnings Yield	8.50%	-	2.13%	5.06%	-	-
FCF Yield	7.20%	-	5.18%	-	-	-
Buyback Yield / Dilution	2.19%	3.10%	1.66%	-70.04%	-9.81%	-51.43%
Total Shareholder Return	2.19%	3.10%	1.66%	-70.04%	-9.81%	-51.43%

SEC Filings: 10-K · 10-Q